Eli Lilly & Company’s recent decision to reduce the price of its weight-loss drug Zepbound (tirzepatide) and offer it as single-use, flexible-dose vials has sparked significant discussion among influencers on social media platform X. The move, intended to enhance affordability and access, has generated a range of sentiments within the industry, reveals the Social Media Analytics Platform of GlobalData.
Tag Archive for: insurance
Since its Change Healthcare unit was breached on Feb. 21 by a hacking group called ALPHV, also known as “BlackCat”, UnitedHealth has said it is working to restore impacted channels, and that some of its systems are returning to normal. While it has not provided a timeline for full recovery, cybersecurity analysts say that is likely quite far off.
President Joe Biden has proposed expansions to the Inflation Reduction Act, including an increase in the annual number of prescription drugs that would be subject to price negotiations to 50, up from 20.
The company said its new program will dramatically decrease costs at the pharmacy counter for patients, including those who are uninsured or underinsured.
The company, however, beat Wall Street estimates for fourth-quarter profit on strength in its drugstores and its pharmacy benefits management (PBM) unit, which negotiates drug prices between insurers and manufacturers.
If you represent or support a pharmaceutical manufacturer, chances are good you’ve seen all the conversation around biosimilars heating up. In July alone, we saw an unprecedented number (seven!) of biosimilars for Humira launch simultaneously. Interestingly, though, if you look at the conversation going on in the marketplace, the bulk of the discussion about which will be adopted and why is focused on behind-the-scenes pricing. However, as many recent reports and our experience indicate, that’s not really what’s standing in the way of adoption.
The survey of 502 employers by Accolade, a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.
Some of the world’s biggest drugmakers are laying legal groundwork to fight the U.S. plan to negotiate drug prices for its Medicare health coverage, including the argument that a ban against speaking about these talks violates constitutional rights, according to industry sources.
French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for a 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.